A detailed history of Sunbelt Securities, Inc. transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Sunbelt Securities, Inc. holds 160,225 shares of AUPH stock, worth $1.33 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
160,225
Previous 185,275 13.52%
Holding current value
$1.33 Million
Previous $928,000 1.51%
% of portfolio
0.1%
Previous 0.11%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$4.81 - $5.78 $120,490 - $144,789
-25,050 Reduced 13.52%
160,225 $914,000
Q1 2024

Apr 15, 2024

SELL
$4.93 - $9.31 $35,865 - $67,730
-7,275 Reduced 3.78%
185,275 $928,000
Q4 2023

Feb 14, 2024

SELL
$7.13 - $9.49 $25,240 - $33,594
-3,540 Reduced 1.81%
192,550 $1.73 Million
Q3 2023

Dec 11, 2023

BUY
$7.77 - $12.27 $924,552 - $1.46 Million
118,990 Added 154.33%
196,090 $1.52 Million
Q2 2023

Aug 15, 2023

BUY
$8.96 - $11.69 $665,280 - $867,982
74,250 Added 2605.26%
77,100 $746,000
Q1 2023

May 17, 2023

BUY
$5.94 - $11.27 $16,929 - $32,119
2,850 New
2,850 $31,000
Q3 2022

Nov 21, 2022

SELL
$6.66 - $12.39 $96,436 - $179,407
-14,480 Closed
0 $0
Q2 2022

Oct 03, 2022

BUY
$8.95 - $12.8 $129,595 - $185,344
14,480 New
14,480 $146,000
Q1 2022

May 16, 2022

SELL
$10.05 - $22.48 $150,599 - $336,862
-14,985 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$17.78 - $33.08 $844,674 - $1.57 Million
-47,507 Reduced 76.02%
14,985 $272,000
Q2 2021

Jul 29, 2021

SELL
$10.0 - $14.52 $344,690 - $500,489
-34,469 Reduced 35.55%
62,492 $703,000
Q1 2021

May 27, 2021

BUY
$12.3 - $18.73 $794,469 - $1.21 Million
64,591 Added 199.54%
96,961 $1.26 Million
Q4 2020

Feb 09, 2021

BUY
$12.94 - $16.05 $418,867 - $519,538
32,370 New
32,370 $448,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.18B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Sunbelt Securities, Inc. Portfolio

Follow Sunbelt Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sunbelt Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sunbelt Securities, Inc. with notifications on news.